Natco Pharma is trading -19.00% lower at Rs 985.45 as compared to its last closing price. Natco Pharma has been trading in the price range of 1,049.35 & 975.00. Natco Pharma has given -4.89% in this year & 11.74% in the last 5 days. Natco Pharma has TTM P/E ratio 13.08 as compared to the sector P/E of 28.63.There are 8 analysts who have initiated coverage on Natco Pharma. There are 1 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 133.00 Crores in its last quarter.Listed peers of Natco Pharma include Wockhardt (-2.73%), Gland Pharma (1.54%), Natco Pharma (-19.00%).The Mutual Fund holding in Natco Pharma was at 1.92% in 31 Dec 2024. The MF holding has decreased from the last quarter. The FII holding in Natco Pharma was at 17.94% in 31 Dec 2024. The FII holding has increased from the last quarter.
Updated on Feb 13, 2025, 06:37 AM UTC
|
|
|
|
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
---|---|---|---|---|---|---|---|---|
Wockhardt | Bullish | 1,473.70 | -2.73 | 23,949.63 | - | 7.3 | - | 31.59 |
Gland Pharma | Moderately Bearish | 1,504.05 | 1.54 | 24,677.61 | 32.35 | 2.86 | 1.32 | 1.62 |
Natco Pharma | Bearish | 985.45 | -19.00 | 17,644.31 | 17.04 | 4.04 | 0.44 | 0.09 |
Eris Lifesciences | - | 1,277.95 | -1.84 | 17,421.04 | 51.12 | 7.78 | - | 26.74 |
Alembic Pharmaceuticals | Bearish | 844.65 | -0.07 | 16,580.77 | 28.38 | 3.62 | 1.24 | 1.31 |
Meeting Date | Purpose |
---|---|
2025-02-12 | Quarterly Results & Interim Dividend |
2024-11-12 | Quarterly Results & Interim Dividend |
2024-08-12 | Quarterly Results & Interim Dividend |
2024-05-27 | Audited Results |
2024-02-14 | Quarterly Results & Interim Dividend |
Natco Pharma is trading at 985.45 as on Thu Feb 13 2025 06:37:03. This is -19.00% lower as compared to its previous closing price of 1216.65.
The market capitalization of Natco Pharma is 17644.31 Cr as on Thu Feb 13 2025 06:37:03.
The average broker rating on Natco Pharma is Hold. The breakup of analyst rating is given below -
The 52 wk high for Natco Pharma is 1638.35 whereas the 52 wk low is 828.50
Natco Pharma can be analyzed on the following key metrics -
Natco Pharma reported a net profit of 1388.30 Cr in 2024.
The Mutual Fund Shareholding was 1.92% at the end of 31 Dec 2024.